JCR Pharmaceuticals (OTCMKTS:JCRRF) Co., Ltd. is a Japan-based biotechnology company specializing in the development, production and commercialization of plasma-derived products and regenerative medicine solutions. The company focuses on manufacturing high-purity plasma proteins, including human serum albumin, immunoglobulins and coagulation factors, to support a range of therapeutic applications in hematology, immunology and critical care settings.
In its plasma-derived business, JCR leverages state-of-the-art fractionation and purification processes to supply products such as intravenous immunoglobulin and albumin formulations. These offerings address clinical needs in areas such as immunodeficiency disorders, severe burn and trauma management, and hemostatic control during surgical procedures. The company’s manufacturing operations adhere to Good Manufacturing Practice standards and serve hospital and specialty pharmacy channels in Japan as well as selected overseas markets.
Beyond traditional plasma therapies, JCR Pharmaceuticals is actively advancing regenerative medicine programs. Its pipeline includes cell-based and gene therapy candidates targeting orthopedic conditions, neuromuscular disorders and other degenerative diseases. These development efforts build on collaborations with academic institutions and contract research organizations to explore novel growth factor–based and cell transplantation modalities.
Headquartered in Kumamoto, Japan, the company operates research and development facilities focused on process innovation and biologics manufacturing. JCR maintains partnerships across Asia, Europe and North America to facilitate clinical development and regulatory submissions. The management team, comprised of industry veterans in pharmaceutical R&D and commercial operations, guides JCR’s strategic expansion into emerging therapeutic areas and global markets.
